Akebia Therapeutics, Inc. - Common Stock (AKBA)

142 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2024.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 56,272,261 shares of 236,234,693 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11,638,484 shares), VANGUARD GROUP INC (9,276,263 shares), Alerce Investment Management, L.P. (5,747,906 shares), GEODE CAPITAL MANAGEMENT, LLC (4,536,292 shares), ACADIAN ASSET MANAGEMENT LLC (4,063,383 shares), RENAISSANCE TECHNOLOGIES LLC (3,914,800 shares), STATE STREET CORP (2,747,240 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2,094,733 shares), Qube Research & Technologies Ltd (1,744,616 shares), and Connor, Clark & Lunn Investment Management Ltd. (1,046,059 shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.